Amryt Pharma Holdings Ltd
LSE:AMYT
Amryt Pharma Holdings Ltd
Revenue
Amryt Pharma Holdings Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
Revenue
$182.6m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£30.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$47.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
Indivior PLC
LSE:INDV
|
Revenue
$1.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$2.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Revenue
£761.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
See Also
What is Amryt Pharma Holdings Ltd's Revenue?
Revenue
182.6m
USD
Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Revenue amounts to 182.6m USD.
What is Amryt Pharma Holdings Ltd's Revenue growth rate?
Revenue CAGR 3Y
131%
Over the last year, the Revenue growth was 214%. The average annual Revenue growth rates for Amryt Pharma Holdings Ltd have been 131% over the past three years .